The U.S. Meals and Drug Administration (FDA) has granted breakthrough remedy designation to ficerafusp alfa together with Keytruda (pembrolizumab) for the primary line remedy of sufferers with metastatic or unresectable, recurrent head and neck squamous cell carcinoma whose tumors categorical PDL1 with mixed constructive rating of a minimum of 1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.
The event was introduced in a information launch issued by Bicara Therapeutics, the clinical-stage biopharmaceutical firm behind ficerafusp alfa. The designation, in keeping with the information launch, underscores the rising reconition of HPV-negative head and neck squamous cell carcinoma as a definite medical indication, and one which has significantly poor outcomes with restricted therapeutic choices.
“This recognition highlights the pressing unmet want for sufferers with HPV-negative [metastatic or unresectable, recurrent head and neck squamous cell carcinoma],” mentioned Dr. David Raben, Chief Medical Officer of Bicara Therapeutics, in a press release within the information launch. “It additionally reinforces our conviction that depth and sturdiness of response, pushed by ficerafusp alfa’s means to synergize with [Keytruda] and allow tumor penetration, are key to attaining long-term medical profit.”
The breakthrough remedy designation, in keeping with the information launch, was supported by the outcomes of a number of section 1 and 1b dose cohorts that had been evaluating the remedy mixture within the first-line setting amongst sufferers with HPV-negative metastatic or unresectable, recurrent head and neck squamous cell carcinoma, with information introduced on the 2025 American Society of Scientific Oncology Annual Assembly demonstrating a median period of response of 21.7 months and a median general survival of 21.3 months with a positive security and tolerability profile.
“[Breakthrough therapy designation] gives exterior validation of the significance of ficerafusp alfa’s best-in-disease potential, and solidifies the inspiration for our ongoing pivotal trial, FORTIFI-HN01,” mentioned Claire Mazumdar, Chief Government Officer of Bicara Therapeutics. “We sit up for working intently with the FDA to deliver this remedy to sufferers as rapidly as attainable.”
It was introduced earlier this 12 months that the primary sufferers had been enrolled within the FORTIFI-HN01 research, a section 2/3 medical trial of ficerafusp alfa together with Keytruda amongst this affected person inhabitants.
“Incidence is rising, but survival charges stay low, significantly for sufferers with HPV-negative illness, underscoring the pressing want for modern remedy choices,” Dr. John Kaczmar of Medical College of South Carolina Hollings Most cancers Heart, mentioned in a information launch issued on the time. “I’m inspired by the early indicators of medical exercise in these sufferers we’ve got seen handled with ficerafusp alfa and hopeful it is going to assist handle this space of serious unmet want.”
The trial, in keeping with its itemizing on clinicaltrials.gov, is actively recruiting sufferers at 50 areas in the US, Canada, Australia and New Zealand. It plans to enroll roughly 650 sufferers, and has an estimated major completion date of April 2028, with an anticipated research completion date of July 2029, in keeping with the itemizing.
Breakthrough Remedy designation, because the FDA explains on its web site, is a course of that’s designed to expedite the event and assessment of medication which might be supposed to deal with a critical situation and preliminary medical proof signifies that the drug might reveal substantial enchancment over obtainable remedy on a clinically vital endpoint.
Ficerafusp alfa, in keeping with the information launch, is a first-in-class bifunctional antibody that’s designed to drive tumor penetration by breaking limitations within the tumor microenvironment which have challenged the remedy of a number of stable tumor cancers, and combines two targets, an EGFR-directed monoclonal antibody with a website that binds to human remodeling development issue beta.
References
- “Bicara Therapeutics Pronounces Ficerafusp Alfa Granted Breakthrough Remedy Designation by U.S. FDA for 1L HPV-Adverse R/M HNSCC,” information launch;
https://www.globenewswire.com/news-release/2025/10/13/3165460/0/en/Bicara-Therapeutics-Pronounces-Ficerafusp-Alfa-Granted-Breakthrough-Remedy-Designation-by-U-S-FDA-for-1L-HPV-Adverse-R-M-HNSCC.html - “Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Most cancers,” CURE;
https://www.curetoday.com/view/ficerafusp-alfa-trial-begins-for-recurrent-metastatic-head-and-neck-cancer - “Breakthrough Remedy,” FDA;
https://www.fda.gov/sufferers/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy - “FORTIFI-HN01: A Research of Ficerafusp Alfa (BCA101) or Placebo in Mixture With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC (FORTIFI-HN01);”
https://www.clinicaltrials.gov/research/NCT06788990#study-overview
For extra information on most cancers updates, analysis and training,
